Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Well, 11 patients are not a whole lot, of course.

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 153778
(Total Views: 856)
Posted On: 05/24/2020 1:16:13 AM
Posted By: Rex Eupseiphos
Re: TechGuru #35178
Quote:
Well, 11 patients are not a whole lot, of course. But one has to use the information one has. For me is better to use 11 patients than no patients at all.



I'd take a good (meaning representative) sample of n = 11 over a bad large sample that does not look like the target population. But that's only half the problem. You need a good sample to compare it to. "88%" is guaranteed to be wrong, but we don't know how wrong or in what direction. I wouldn't put much faith in that number AT ALL. The problem is that for that number to make any sense, the population it is derived from has to be the same that the 10 (or 11) are derived from. And, no, I mean "population" in the statistical sense (patient condition and treatment), not in the demographic sense (e.g. NY area). Otherwise the statistics are bunk.

Did the patients that the 88% estimate (not fixed reality --- critical distinction in statistics!) come from have the condition (severity of condition, length of time since initial infection, prior treatment, age, comorbidities), the same treatment, and the same measure of mortality (in the study you cite, the odds of mortality are calculated as fatalities:discharges. What about the fates of the patients who were living but still in the hospital? Same as in the Montefiore cohort? No idea. These are crucial questions, which is part of the reason clinical trials are so blinkin' hard to set up. Unless they are carefully dealt with, the "statistics" are garbage if you try to make inference beyond your sample.

And my objection to your "what FDA does" comment is not that there's anything wrong with the binomial distribution (one might even say that my entire professional life as a statistician for the past 8 years or so has been working with elaborations of binomial RVs...and other discrete distributions for the 17 years before that!), but that there's a world of difference between a two-sample test and a one-sample test, and they will certainly use two-sample tests.


(3)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us